TF and neoplasm: We have thus far generated a novel and specific TF monoclonal antibody SC1, which displayed exceedingly high inhibition potency against TF extracellular domain, TF-overexpressing TNBC or PaC cells, PAR2 signaling and tumor TF-initiated coagulation.